Combination therapy for treatment of ovarian cancer
This invention relates to methods of treating a patient with ovarian cancer having deficiencies in homologous recombination (HR) comprising administering to the patient (i) an effective amount of ganetespib, or a pharmaceutically acceptable salt thereof; and (ii) an effective amount of a DNA-damaging or repair-inhibiting agent.
1. A method of treating a patient with ovarian cancer, comprising administering to the patient (i) an effective amount of ganetespib, or a pharmaceutically acceptable salt thereof; and (ii) an effective amount of cisplatin, wherein the ovarian cancer has been determined to have deficiencies in homologous recombination (HR).
2. The method of claim 1 , wherein the ovarian cancer determined to have deficiencies in homologous recombination (HR) has a homologous recombination deficiency (HRD) score of greater than 40.
3. The method of claim 1 , wherein the ovarian cancer is epithelial ovarian cancer.
4. The method of claim 1 , wherein the ovarian cancer determined to have deficiencies in homologous recombination (HR) has a homologous recombination deficiency (HRD) score of >42.
5. The method of claim 1 , wherein the ovarian cancer determined to have deficiencies in HR has a homologous recombination deficiency (HRD) score that is calculated based on loss of heterozygosity (LOH), large scale transitions (LST), and telomeric allelic imbalance (TAI).
6. The method of claim 5 , wherein the HRD score is calculated according to the following formula:
HRD -model=011× HRD - LOH+ 0.25× HRD - TAI+ 0.12× NRD - LST.
7. A method of treating a patient with ovarian cancer, comprising the steps of:
a) screening the ovarian cancer of the patient to determine that it is HR deficient; and
b) administering to the patient an effective amount of ganetespib or a pharmaceutically acceptable salt thereof and an effective amount of cisplatin.